India Global Drug Regulatory Conclave 2026
Analysis based on 7 articles · First reported Jul 31, 2026 · Last updated Jul 31, 2026
The conclave signals India's intent to harmonize its drug regulatory standards with global norms, potentially easing market access for Indian pharmaceutical exports and attracting foreign investment. The planned digital regulatory platform could streamline approvals, benefiting both domestic and international drug manufacturers operating in India.
India hosted the two-day Global Drug Regulatory Conclave 2026 in New Delhi, bringing together heads and senior officials of national drug regulatory authorities from around the world. Commerce and Industry Minister Piyush Goyal emphasized India's push for closer cooperation among global medicine regulators, supported by its expanding network of trade agreements, to enable faster access to high-quality, affordable medicines and strengthen India's position as a global pharmaceutical innovation hub. Health Minister Jagad Prakash Nadda stressed the importance of trusted, science-based regulatory systems for public health and innovation, reaffirming India's commitment to a future-ready regulatory ecosystem through reforms and digital transformation. Drugs Controller General of India Dr. Rajeev Singh Raghuvanshi announced that the India — Central Drugs Standard Control Organisation (CDSCO) will roll out the first phase of an end-to-end digital drug regulatory platform within the next 18 months. The conclave, organized by India — Pharmexcil, aims to foster collaboration between India's pharmaceutical industry, global regulators, and stakeholders. Goyal also highlighted India's nine free trade agreements with $60 trillion in market access and a 73% surge in exports over the past five years under Prime Minister Narendra Modi's leadership.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard